October 16, 2025: County Public Health Confirms Its First Case of Clade I Mpox - Case not linked to travel; Public health urges vaccination, testing, and prevention. Click here to read the press release.
Those at risk for or seeking additional protection from mpox infection are encouraged to get vaccinated. Anyone who requests vaccination can receive it in Los Angeles County without having to disclose information on personal risk.
Who should get the vaccine:
In alignment with California Department of Public Health's recommendations, the mpox vaccine (JYNNEOS) is recommended for any person who:
In addition, the mpox vaccine is recommended for anyone at occupational risk for exposure to mpox (e.g., certain laboratory workers).
*These recommendations are intended to simplify risk assessment and increase vaccination coverage among groups at increased risk of exposure given current outbreak data. Talk with your healthcare provider if you are unsure if you may be at risk for mpox.
Currently, routine immunization against mpox for the general public is not recommended.
Who should NOT get the vaccine:
If you have insurance, talk to your doctor or check with your local pharmacy to see what vaccines are offered. Most health insurances cover the cost of all recommended vaccines for eligible children and adults. Contact your health plan first to find out if they cover JYNNEOS and call ahead to make sure the JYNNEOS vaccine is available in advance of going to your vaccine provider.
LA County DPH Sexual Health Clinics offer JYNNEOS to individuals who are uninsured or underinsured. Call in advance to make an appointment and confirm vaccine availability. You may visit this site to access contact information, hours of operation, and appointment scheduling details: http://publichealth.lacounty.gov/chs/sexualhealthclinics/
If you are an uninsured or underinsured adult, you may be able to access low or no cost JYNNEOS vaccine at select locations that carry the vaccine, including federally qualified health centers. Some of these locations are listed on the local mpox vaccination referral sites list. You may also visit the Bavarian Nordic (JYNNEOS vaccine manufacturer) vaccine locator to search for vaccination sites near you.
Other programs or plans may cover the vaccine cost for people who are eligible, including:
Youth Under Age 18
If you are an uninsured or underinsured person aged 18 years or younger, you may be eligible to receive vaccines at no cost through the Vaccines for Children (VFC) Program if you are:
Consent for Minors
If you are unsure of your mpox vaccination status or cannot locate your records, here are some options.
If you need official copies of your vaccine records, or if you need to update your personal records:
For information on mpox clinical presentation, testing, treatment, reporting, and clinical consultation, please visit the LA County Public Health Mpox Resource Page for providers.
The Los Angeles County Department of Public Health recommends vaccination for anyone at risk of mpox infection or seeking additional protection. Vaccination is available without disclosure of personal risk.
Details regarding the Mpox vaccine schedule, post-exposure prophylaxis (PEP), and co-administration, can be found on CDC’s Interim Clinical Guidance Considerations for Use of Vaccine for Mpox Prevention in the United States webpage.
Mpox Vaccination & Post-Exposure Prophylaxis (PEP) Schedule:
| Vaccine | Administration Route | Volume per Dose | Number of Doses | Schedule | Use | Notes |
|---|---|---|---|---|---|---|
| JYNNEOS |
Subcutaneous (SC) | 0.5 mL | 2 doses | 0 and 28 days | Routine & PEP | Licensed for individuals aged 18 and older. For those under 18, administration is via SC route under Emergency Use Authorization (EUA). |
| JYNNEOS | Intradermal (ID) | 0.1 mL | 2 doses | 0 and 28 days | Routine & PEP | Authorized under EUA for individuals aged 18 and older. Providers should discuss patient preference/choice for route of administration with patients aged 18 and older. ID route is not recommended for those with history of keloid scars; SC route is preferred in such cases. |
| ACAM2000 | Percutaneous (Scarification) |
0.0025 mL (one drop) |
1 dose | Single dose | Routine & PEP (If JYNNEOS is unavailable) | Contains live vaccinia virus that replicates in humans. Not recommended for immunocompromised individuals, those with certain skin conditions, or pregnant women due to higher risk of adverse effects. Not used in the current outbreak. |
Post-Exposure Prophylaxis (PEP) Guidance:
| Exposure Risk Level | Recommended |
|---|---|
| High or Intermediate Risk | -Vaccination: Administer JYNNEOS as soon as possible, ideally within
4 days of exposure to prevent Mpox. If given between 4 to 14 days, vaccination may reduce symptoms but might not prevent the disease.
-Vaccine Details: Two doses of JYNNEOS (0.5 mL SC or 0.1 mL ID) given 28 days apart. -Alternative Vaccine: ACAM2000 may be used if JYNNEOS is unavailable, but it has a higher risk of adverse effects and is not suitable for immunocompromised individuals. |
| Low or Uncertain Risk | -Vaccination: Not routinely recommended.
-Action: Conduct an individual risk assessment to determine the need for PEP. |
Additional Considerations:
For full guidance, visit CDPH's Mpox Vaccination Resources page.
Proper vaccine storage and handling practices play an important role. For general recommendations and guidance access the Vaccine Storage and Handling Toolkit.
CDC Clinical Resources
JYNNEOSTM Vaccine Information